Core Insights - Entero Therapeutics, Inc. (ENTO) has acquired 100% of GRID AI Corp, positioning itself in the high-growth AI energy-infrastructure market amid increasing hyperscaler spending on data centers and energy storage solutions [2][3] Industry Overview - The AI-driven workloads are expected to significantly increase electricity consumption from data centers, with Goldman Sachs projecting a ~50% rise in global data-center power demand by 2027 and up to 165% by 2030 compared to 2023 [4] - Hyperscaler capital expenditures are surging, with estimates indicating annual spending in the hundreds of billions, and AI-related infrastructure investments projected to exceed $2.8 trillion by 2029 [5] Company Strategy - The acquisition of GRID AI allows ENTO to leverage GRID AI's Dynamic Load Shaping™ platform to manage localized loads from AI data centers while integrating renewable energy sources [6][12] - ENTO aims to scale solutions that address AI-driven power demand and improve grid reliability for both consumers and enterprises [3][12] Transaction Details - Under the acquisition agreement, former GRID AI shareholders will own approximately 82.5% of the fully diluted ENTO common stock, while existing ENTO shareholders will retain about 17.5% [8] - The transaction includes provisions for the former GRID AI shareholders to appoint directors to ENTO's board, enhancing governance and strategic alignment [8] Future Outlook - The acquisition positions ENTO within a growing market at the intersection of AI and energy, with strong tailwinds and opportunities for recurring revenue through GRID AI's SaaS-like model targeting utilities and retailers [12] - ENTO plans to operate GRID AI as a wholly owned subsidiary while continuing its existing biopharmaceutical operations, thus diversifying its portfolio into critical infrastructure software [10][12]

Core Insights - Entero Therapeutics, Inc. is recognized as one of the 15 best biotech penny stocks to invest in, focusing on targeted therapies for gastrointestinal disorders [1] - The company underwent a leadership change with Jason D. Sawyer appointed as the new CEO, indicating a strategic shift towards new funding and partnership opportunities [2] - Entero Therapeutics completed a $3 million private placement to enhance liquidity for working capital and ongoing research [4] Company Developments - The company is developing therapies for conditions such as celiac disease, gastroparesis, and pancreatic insufficiency [1] - The recent 1-for-3 reverse stock split was implemented to maintain Nasdaq compliance, which has led to market volatility and investor caution [3] - Key pipeline initiatives include Adrulipase, a recombinant lipase therapy for cystic fibrosis and chronic pancreatitis, along with investigational treatments for celiac disease [4]

As filed with the Securities and Exchange Commission on September 10, 2025 Registration Statement No. 333-289864 UNITED STATES SECURITIES AND EXCHANGE COMMISSION (State or other jurisdiction of incorporation or organization) Delaware 2834 46-4993860 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Washington, D.C. 20549 777 Yamato Road, Suite 502 Boca Raton, Florida 33431 (561) 589-7020 (Address, including zip code, and telephone number, including area code, o ...

As filed with the Securities and Exchange Commission on September 10, 2025 Registration Statement No. 333-289864 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENTERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 46-4993860 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer ...

As filed with the Securities and Exchange Commission on August 26, 2025 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENTERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 46-4993860 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 777 Y ...

As filed with the Securities and Exchange Commission on August 26, 2025 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENTERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 46-4993860 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 777 Y ...

Core Viewpoint - Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split to comply with Nasdaq listing requirements, aiming to enhance shareholder value and maintain its market presence [1][2][4]. Company Actions - The reverse stock split was approved by the Board of Directors and shareholders, and it will take effect on August 18, 2025, with trading on a split-adjusted basis [2][1]. - The reverse split will consolidate approximately 4.77 million shares into about 1.59 million shares, eliminating fractional shares by providing cash compensation instead [3][1]. Management Commentary - Richard Paolone, Interim CEO, emphasized the necessity of the reverse split for maintaining Nasdaq listing, which is crucial for increasing visibility and credibility, thereby enhancing shareholder value [4]. Company Overview - Entero Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing targeted, non-systemic therapies for gastrointestinal diseases, including Adrulipase for patients with exocrine pancreatic insufficiency [4].